A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

To find a recommended dose of attIL2-T cell therapy that can be given to patients with soft tissue or bone sarcomas and to see if it can help to control the disease.

Trial Details

NCT ID
NCT05621668
Phase
PHASE1
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Cyclophosphamide
  • attIL2-T cells
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Age .12 years old
  • Histologically-confirmed locally advanced or metastatic soft tissue or bone sarcoma
  • Osteosarcoma expansion cohort: histologically confirmed unresectable recurrent/metastatic osteosarcoma
  • Evaluable disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →